Alcohol

Alcohol

SCHEMBL697179

CCO.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Alcohol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.67
TSHR P16473 3/20 0.67
TDP1 Q9NUW8 2/20 0.33
HSD17B10 Q99714 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Alcohol SCHEMBL9275621 1.00 ALDH1A1 (0.67) ALDH1A1TSHRTDP1HSD17B10SMN1; SMN2
Alcohol SCHEMBL1931178 1.00 ALDH1A1 (0.67) ALDH1A1TSHRTDP1HSD17B10SMN1; SMN2
Alcohol SCHEMBL8027671 1.00 ALDH1A1 (0.67) ALDH1A1TSHRTDP1HSD17B10SMN1; SMN2
Alcohol SCHEMBL6028274 1.00 ALDH1A1 (0.67) ALDH1A1TSHRTDP1HSD17B10SMN1; SMN2
Alcohol SCHEMBL5556136 1.00 ALDH1A1 (0.67) ALDH1A1TSHRTDP1HSD17B10SMN1; SMN2
Alcohol SCHEMBL6554416 1.00 ALDH1A1 (0.67) ALDH1A1TSHRTDP1HSD17B10SMN1; SMN2
Alcohol SCHEMBL4458809 1.00 ALDH1A1 (0.67) ALDH1A1TSHRTDP1HSD17B10SMN1; SMN2
Alcohol SCHEMBL2652301 1.00 ALDH1A1 (0.67) ALDH1A1TSHRTDP1HSD17B10SMN1; SMN2
Alcohol SCHEMBL10709971 1.00 ALDH1A1 (0.67) ALDH1A1TSHRTDP1HSD17B10SMN1; SMN2
Alcohol SCHEMBL1836225 1.00 ALDH1A1 (0.67) ALDH1A1TSHRTDP1HSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101398489-B Optical film, polarizing plate and image display device FUJIFILM CORP 2012-07-11 CN disclosed
EP-2423207-A2 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors Mitsubishi Tanabe Pharma Corporation (JP) 2012-02-29 EP disclosed
CN-101398489-A Optical film, polarizing plate and image display device FUJIFILM CORP (JP) 2009-04-01 CN disclosed
EP-2001863-A1 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES AS TPK1 INHIBITORS Mitsubishi Tanabe Pharma Corporation (JP) 2008-12-17 EP disclosed
EP-1660085-B1 PYRIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PFIZER ITALIA SRL (IT) 2008-10-15 EP disclosed
WO-2007119463-A1 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES AS TPK1 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-10-25 WO disclosed
US-7081468-B2 Ortho-substituted anthranilic acid amides and their use as medicaments SCHERING AG (DE) 2006-07-25 US disclosed
EP-1660085-A1 PYRIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2006-05-31 EP disclosed
US-20060014747-A1 Ortho-substituted anthranilic acid amides and their use as pharmaceutical agents BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2006-01-19 US disclosed
US-20050043346-A1 Pyridylpyrrole derivatives active as kinase inhibitors PHARMACIA ITALIA S.P.A. (IT) 2005-02-24 US disclosed
WO-2005013986-A1 PYRIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2005-02-17 WO disclosed
EP-0751144-B1 Novel anthracycline prodrugs, method for preparation as well as their use in selective chemotherapy PHARMACHEMIE BV (NL) 2004-10-06 EP disclosed
US-20040102441-A1 Ortho-substituted anthranilic acid amides and their use as medicaments BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2004-05-27 US disclosed
US-5710135-A ENZYMATICALLY CLEAVABLE; ANTITUMOR AGENTS PHARMACHEMIE B.V. (NL) 1998-01-20 US disclosed
EP-0751144-A1 Novel anthracycline prodrugs, method for preparation as well as their use in selective chemotherapy PHARMACHEMIE B.V. (NL) 1997-01-02 EP disclosed
WO-1996012725-A1 NOVEL QUINOXALINDIONE DERIVATIVES, THEIR PRODUCTION AND USE IN MEDICAMENTS SCHERING AKTIENGESELLSCHAFT (DE) 1996-05-02 WO disclosed
US-5403572-A Macrocyclic polyaza compounds containing 5 or 6 membered rings, process for producing them and pharmaceutical media containing them SCHERING AKTIENGESELLSCHAFT (DE) 1995-04-04 US disclosed
US-5334371-A Marcocyclic polyaza bicyclo compounds containing 5 or 6 membered rings, and method for MRI SCHERING AKTIENGESELLSCHAFT (DE) 1994-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043346-A1 Pyridylpyrrole derivatives active as kinase inhibitors MAP3K6, MAP3K5, MAP4K2 ALDH1A1 2319/4885TSHR 1858/4885TDP1 1002/4885
US-20060014747-A1 Ortho-substituted anthranilic acid amides and their use as pharmaceutical agents VEGFA, TEK, OGFR ALDH1A1 1187/4885TSHR 1553/4885TDP1 4694/4885
US-20040102441-A1 Ortho-substituted anthranilic acid amides and their use as medicaments TEK, VEGFA, ASPH ALDH1A1 1414/4885TSHR 2181/4885TDP1 4647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.